Analysts Set Alder Biopharmaceuticals Inc (ALDR) PT at $21.20

Share on StockTwits

Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) have been given a consensus rating of “Hold” by the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.20.

ALDR has been the topic of several research analyst reports. BidaskClub lowered Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Cantor Fitzgerald restated a “hold” rating and set a $14.00 target price on shares of Alder Biopharmaceuticals in a research report on Thursday, May 2nd. ValuEngine upgraded Alder Biopharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, January 30th. Zacks Investment Research upgraded Alder Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Tuesday, April 30th. Finally, Canaccord Genuity cut their target price on Alder Biopharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 14th.

In related news, EVP James B. Bucher sold 1,897 shares of the company’s stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the sale, the executive vice president now owns 11,706 shares in the company, valued at approximately $162,128.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 17.40% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co NY raised its stake in Alder Biopharmaceuticals by 178.7% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 59,959 shares of the biopharmaceutical company’s stock worth $2,630,000 after buying an additional 38,442 shares during the period. Marshall Wace LLP acquired a new position in Alder Biopharmaceuticals during the 1st quarter worth approximately $289,000. Geode Capital Management LLC raised its stake in Alder Biopharmaceuticals by 33.9% during the 1st quarter. Geode Capital Management LLC now owns 868,135 shares of the biopharmaceutical company’s stock worth $11,850,000 after buying an additional 219,695 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Alder Biopharmaceuticals by 17.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 381,373 shares of the biopharmaceutical company’s stock worth $5,206,000 after buying an additional 56,183 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in Alder Biopharmaceuticals by 88.1% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 85,625 shares of the biopharmaceutical company’s stock worth $1,169,000 after buying an additional 40,100 shares during the period. Institutional investors own 85.68% of the company’s stock.

NASDAQ ALDR opened at $11.12 on Monday. Alder Biopharmaceuticals has a 12 month low of $9.44 and a 12 month high of $20.87. The stock has a market capitalization of $921.05 million, a price-to-earnings ratio of -2.28 and a beta of 2.74. The company has a debt-to-equity ratio of 1.21, a quick ratio of 8.34 and a current ratio of 8.34.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.47). Equities research analysts expect that Alder Biopharmaceuticals will post -4.47 EPS for the current year.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Recommended Story: Book Value Per Share – BVPS

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ares Commercial Real Estate Corp Declares Quarterly Dividend of $0.33
Ares Commercial Real Estate Corp Declares Quarterly Dividend of $0.33
Equity Lifestyle Properties, Inc.  to Issue Quarterly Dividend of $0.61
Equity Lifestyle Properties, Inc. to Issue Quarterly Dividend of $0.61
Stryker Co. Declares Quarterly Dividend of $0.52
Stryker Co. Declares Quarterly Dividend of $0.52
Agree Realty Co.  Plans Quarterly Dividend of $0.57
Agree Realty Co. Plans Quarterly Dividend of $0.57
$0.01 Earnings Per Share Expected for CRH Medical Corporation  This Quarter
$0.01 Earnings Per Share Expected for CRH Medical Corporation This Quarter
Vermilion Energy Inc  Receives $35.67 Consensus Target Price from Brokerages
Vermilion Energy Inc Receives $35.67 Consensus Target Price from Brokerages


© 2006-2019 Ticker Report